Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients

29 Oct 2018

Abstract excerpt

BACKGROUND: Prostate cancer (PCa) is one of the most common cancers among men worldwide. Current screening methods for PCa display limited sensitivity and specificity, not stratifying for disease aggressiveness. Hence, development and validation of new molecular markers is needed. Aberrant gene promoter methylation is common in PCa and has shown promise as clinical biomarker. Herein, we assessed and compared the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30373654
DOI: 10.1186/s13148-018-0564-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patientsPMID 30373654Read ↗

MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumorsSemantic proximity Read ↗

A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancerSemantic proximity Read ↗

Prognostic DNA Methylation Markers for Prostate CancerSemantic proximity Read ↗

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate CancerSemantic proximity Read ↗

Epigenetic Markers for Molecular Detection of Prostate CancerSemantic proximity Read ↗

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer TypesSemantic proximity Read ↗

A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNASemantic proximity Read ↗

DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non‐invasive detectionSemantic proximity Read ↗

Prediction of Prognosis in Patients with Prostate Cancer by DNA Methylation ClassificationSemantic proximity Read ↗

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate CancerSemantic proximity Read ↗

DNA methylation alterations in prostate cancer: from diagnosis to treatmentSemantic proximity Read ↗

Advances in Prognostic Methylation Biomarkers for Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.